Literature DB >> 23847214

Breast cancer, version 3.2013: featured updates to the NCCN guidelines.

Richard L Theriault1, Robert W Carlson, Craig Allred, Benjamin O Anderson, Harold J Burstein, Stephen B Edge, William B Farrar, Andres Forero, Sharon Hermes Giordano, Lori J Goldstein, William J Gradishar, Daniel F Hayes, Clifford A Hudis, Steven J Isakoff, Britt-Marie E Ljung, David A Mankoff, P Kelly Marcom, Ingrid A Mayer, Beryl McCormick, Lori J Pierce, Elizabeth C Reed, Lee S Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H Ward, Antonio C Wolff, Richard Zellars, Dorothy A Shead, Rashmi Kumar.   

Abstract

These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23847214      PMCID： PMC3991132          DOI： 10.6004/jnccn.2013.0098

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  15 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

Review 2.  HER2 testing in breast cancer: NCCN Task Force report and recommendations.

Authors:  Robert W Carlson; Susan J Moench; M Elizabeth H Hammond; Edith A Perez; Harold J Burstein; D Craig Allred; Charles L Vogel; Lori J Goldstein; George Somlo; William J Gradishar; Clifford A Hudis; Mohammad Jahanzeb; Azadeh Stark; Antonio C Wolff; Michael F Press; Eric P Winer; Soonmyung Paik; Britt-Marie Ljung
Journal:  J Natl Compr Canc Netw       Date:  2006-07       Impact factor: 11.908

3.  HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

Authors:  Edith A Perez; Vera J Suman; Nancy E Davidson; Silvana Martino; Peter A Kaufman; Wilma L Lingle; Patrick J Flynn; James N Ingle; Daniel Visscher; Robert B Jenkins
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

4.  Semisynthetic maytansine analogues for the targeted treatment of cancer.

Authors:  Wayne C Widdison; Sharon D Wilhelm; Emily E Cavanagh; Kathleen R Whiteman; Barbara A Leece; Yelena Kovtun; Victor S Goldmacher; Hongsheng Xie; Rita M Steeves; Robert J Lutz; Robert Zhao; Lintao Wang; Walter A Blättler; Ravi V J Chari
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

5.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Authors:  Soonmyung Paik; John Bryant; Elizabeth Tan-Chiu; Edward Romond; William Hiller; Kyeongmee Park; Ann Brown; Greg Yothers; Steve Anderson; Roy Smith; D Lawrence Wickerham; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

6.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

Authors:  Patrick C Roche; Vera J Suman; Robert B Jenkins; Nancy E Davidson; Silvana Martino; Peter A Kaufman; Ferdinand K Addo; Bronagh Murphy; James N Ingle; Edith A Perez
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

7.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

8.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Authors:  José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

9.  Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

Authors:  Werner Scheuer; Thomas Friess; Helmut Burtscher; Birgit Bossenmaier; Josef Endl; Max Hasmann
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

10.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.

Authors:  Shaheenah Dawood; Kristine Broglio; Aman U Buzdar; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544
View more
  71 in total

Review 1.  Present and future role of FDG-PET/CT imaging in the management of breast cancer.

Authors:  Kazuhiro Kitajima; Yasuo Miyoshi
Journal:  Jpn J Radiol       Date:  2016-01-05       Impact factor: 2.374

2.  Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.

Authors:  Raffaella Palumbo; Federico Sottotetti; Alberto Riccardi; Cristina Teragni; Emma Pozzi; Erica Quaquarini; Barbara Tagliaferri; Antonio Bernardo
Journal:  Ther Adv Med Oncol       Date:  2013-11       Impact factor: 8.168

3.  PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer.

Authors:  Honggeng Guan; Yang Lan; Yuqiu Wan; Qin Wang; Cheng Wang; Longjiang Xu; Yongjing Chen; Wenting Liu; Xueguang Zhang; Yecheng Li; Yongping Gu; Zemin Wang; Fang Xie
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

4.  Association between the ornithine decarboxylase G316A polymorphism and breast cancer survival.

Authors:  Linping Xu; Jianping Long; Peng Wang; Kangdong Liu; Ling Mai; Yongjun Guo
Journal:  Oncol Lett       Date:  2015-05-12       Impact factor: 2.967

5.  Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.

Authors:  Michael D Hambuchen; F Ivy Carroll; Daniela Rüedi-Bettschen; Howard P Hendrickson; Leah J Hennings; Bruce E Blough; Lawrence E Brieaddy; Ramakrishna R Pidaparthi; S Michael Owens
Journal:  J Med Chem       Date:  2015-05-22       Impact factor: 7.446

Review 6.  Primary metastatic breast cancer: the impact of locoregional therapy.

Authors:  Steffi Hartmann; Toralf Reimer; Bernd Gerber; Angrit Stachs
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

7.  A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.

Authors:  Jae-Hyeog Choi; Ki Hyang Kim; Kug-Hwan Roh; Hana Jung; Anbok Lee; Ji-Young Lee; Joo Yeon Song; Seung Jae Park; Ilhwan Kim; Won-Sik Lee; Su-Kil Seo; Il-Whan Choi; Yang-Xin Fu; Sung Su Yea; SaeGwang Park
Journal:  Oncoimmunology       Date:  2018-01-16       Impact factor: 8.110

Review 8.  Genomic profiling in luminal breast cancer.

Authors:  Oleg Gluz; Daniel Hofmann; Rachel Würstlein; Cornelia Liedtke; Ulrike Nitz; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

Review 9.  The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review.

Authors:  Ioannis Bakoyiannis; Eleousa-Alexandra Tsigka; Despina Perrea; Vasilios Pergialiotis
Journal:  Clin Drug Investig       Date:  2016-02       Impact factor: 2.859

10.  Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I-II and operable stage III breast cancer.

Authors:  Xiying Shao; Lei Luo; Yong Guo; Xiaohong Xu; Dehou Deng; Jianguo Feng; Yuheng Ding; Hanzhou Mou; Ping Huang; Lei Shi; Yuan Huang; Weiwu Ye; Caijin Lou; Zhanhong Chen; Yabing Zheng; Xiaojia Wang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.